Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses
Single-vial thermostabilized bivalent vaccine demonstrates simultaneous protection against two lethal viruses
PRINCETON, N.J., Jan. 2, 2024 /PRNewswire/ — Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today a publication describing the preclinical efficacy of a novel, single-vial, bivalent vaccine providing 100% protection against both Sudan ebolavirus (SUDV) and Marburg marburgvirus (MARV) infections. In collaboration with University of Hawaiʻi at Mānoa (UHM), the manuscript entitled “Thermostable bivalent filovirus vaccine protects against severe and lethal Sudan ebolavirus and marburgvirus infection“, has been published in Vaccine.
Related news for (SNGX)
- Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma
- Soligenix Announces Closing of $7.5 Million Public Offering
- Soligenix Announces Pricing of $7.5 Million Public Offering
- Breaking News: MoBot’s Latest Update as of 09/23/25 07:00 AM
- Soligenix Announces Appointment of Former White House Economic Adviser Tomas J. Philipson, PhD as Strategic Advisor